Published in Br J Clin Pharmacol on January 01, 2009
Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol (2010) 1.21
Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci (2010) 1.16
Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One (2011) 1.08
CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol (2011) 0.97
Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol (2013) 0.93
Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab Dispos (2010) 0.92
Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology (2012) 0.91
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol (2013) 0.89
Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir. Drug Metab Dispos (2013) 0.87
Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology (2015) 0.83
Methadone and metabolites in hair of methadone-assisted pregnant women and their infants. Ther Drug Monit (2012) 0.80
S-Methadone augments R-methadone induced respiratory depression in the neonatal guinea pig. Respir Physiol Neurobiol (2009) 0.78
Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. Clin Pharmacol Ther (2015) 0.78
Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy. Front Pharmacol (2015) 0.76
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of methadone in a sample of Iranian (mazandarani) opiate users undergoing methadone maintenance treatment. Iran J Psychiatry Behav Sci (2011) 0.75
Pharmacogenomic considerations in opioid analgesia. Pharmgenomics Pers Med (2012) 0.75
Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA (1999) 5.29
Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther (1997) 2.33
A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry (1996) 2.23
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet (2002) 1.96
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther (1996) 1.85
Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality (2004) 1.69
A six-year evaluation of methadone prescribing practices at a substance misuse treatment centre in the UK. J Clin Pharm Ther (2006) 1.58
Methadone dose and urine morphine. J Subst Abuse Treat (1991) 1.55
Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry (1989) 1.53
ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther (2006) 1.49
Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother (2000) 1.49
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther (2005) 1.45
Therapeutic drug monitoring for methadone: scanning the horizon. Eur Addict Res (1999) 1.43
Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med (1993) 1.41
Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend (2002) 1.40
Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol (1996) 1.39
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol (1999) 1.33
Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend (1998) 1.32
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther (1999) 1.32
The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther (1972) 1.27
Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol (2000) 1.23
Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos (2003) 1.22
Increased brain P-glycoprotein in morphine tolerant rats. Life Sci (2000) 1.17
The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol (2001) 1.16
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS (1999) 1.15
Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis (2001) 1.12
Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos (1998) 1.11
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther (1993) 1.09
The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos (1997) 1.09
Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet (2003) 1.09
Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend (2000) 1.09
Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit (1990) 1.08
Measuring compliance in methadone maintenance patients: use of a pharmacologic indicator to "estimate" methadone plasma levels. Clin Pharmacol Ther (1991) 1.05
Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol (2004) 1.03
The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol (1999) 1.02
Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther (2001) 1.01
Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther (1992) 1.00
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther (1992) 0.95
Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit (2001) 0.94
Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol (1981) 0.94
Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol (1997) 0.93
Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol (1995) 0.93
High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry (1998) 0.92
Methadone, ciprofloxacin, and adverse drug reactions. Lancet (2000) 0.91
Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther (1973) 0.91
The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther (1998) 0.90
Methadone maintenance treatment and St. John's Wort - a case report. Pharmacopsychiatry (2003) 0.90
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol (2003) 0.90
Stereoselective determination of methadone and the primary metabolite EDDP in human plasma by automated on-line extraction and liquid chromatography mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.89
Rapid quantitative liquid chromatographic determination of caffeine levels in plasma after oral dosing. J Pharm Sci (1984) 0.89
Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend (2003) 0.88
Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man. Br J Clin Pharmacol (1989) 0.88
CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics (1997) 0.87
Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient? Ther Drug Monit (2001) 0.87
Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther (1998) 0.85
Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther (2001) 0.85
An alternative method for population pharmacokinetic data analysis under noncompliance. J Pharmacokinet Pharmacodyn (2008) 0.85
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 0.85
Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy (1999) 0.84
Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med (2000) 0.83
Efavirenz decreases methadone blood concentrations. AIDS (2000) 0.83
Rated well-being in relation to plasma concentrations of l- and d-methadone in satisfied and dissatisfied patients on methadone maintenance treatment. Psychopharmacology (Berl) (1999) 0.82
Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem (1992) 0.79
Can saliva replace plasma for the monitoring of methadone? Ther Drug Monit (2005) 0.79
Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. AIDS (1998) 0.79
Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses. Clin Pharmacol Ther (1977) 0.79
Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone. Am J Psychiatry (1990) 0.78
Impact of long-term ethanol consumption on CYP1A2 activity. Clin Pharmacol Ther (1997) 0.77
Chronic heroin use during methadone treatment: a test of the efficacy of high maintenance doses. Addict Behav (1984) 0.76
Slow metabolism and long half life of methadone in a patient with lung cancer and cirrhosis. Ann Med Interne (Paris) (2001) 0.76
Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet (2013) 2.22
Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos (2002) 1.92
The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol (2009) 1.88
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet (2006) 1.69
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov (2007) 1.63
Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol (2004) 1.61
Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab (2009) 1.57
A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet (2009) 1.56
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet (2011) 1.55
Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl (2005) 1.41
Population-based mechanistic prediction of oral drug absorption. AAPS J (2009) 1.38
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet (2012) 1.36
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet (2010) 1.34
Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth (2011) 1.31
Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) (2004) 1.22
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab (2007) 1.22
Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab (2008) 1.22
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer (2005) 1.16
Prevalence of personality disorder in alcohol and drug services and associated comorbidity. Addiction (2004) 1.15
Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach. Clin Pharmacokinet (2015) 1.09
Prediction of intestinal first-pass drug metabolism. Curr Drug Metab (2007) 1.09
Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol (2015) 1.06
Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol (2005) 1.03
The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Ind Pharm (2007) 1.02
Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol (2006) 0.99
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol (2012) 0.97
Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol (2011) 0.97
Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol (2013) 0.95
Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther (2004) 0.94
The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol (2008) 0.92
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol (2014) 0.91
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos (2013) 0.91
Pharmacometrics in pregnancy: An unmet need. Annu Rev Pharmacol Toxicol (2014) 0.91
Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. Biopharm Drug Dispos (2015) 0.89
Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos (2007) 0.89
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos (2011) 0.89
Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab (2010) 0.89
Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol (2008) 0.89
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol (2011) 0.88
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies -CYP2C9 and warfarin as an example. Br J Clin Pharmacol (2007) 0.88
Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol (2013) 0.87
Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol (2012) 0.86
The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci (2003) 0.86
Post-treatment outcomes of buprenorphine detoxification in community settings: a systematic review. Eur Addict Res (2008) 0.86
Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP). Toxicol Lett (2004) 0.85
Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos (2014) 0.85
Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol (2004) 0.85
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. J Pharm Pharmacol (2012) 0.84
A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet (2014) 0.84
Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J Pharm Sci (2013) 0.83
PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions. J Psychopharmacol (2007) 0.83
Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. J Pharm Sci (2012) 0.83
Fraction absorbed (Fabs ): different connotations and confusion for the literature? Biopharm Drug Dispos (2011) 0.82
An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. Br J Clin Pharmacol (2002) 0.82
Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica (2011) 0.82
Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol (2009) 0.81
Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci (2013) 0.81
The generation, detection, and effects of reactive drug metabolites. Med Res Rev (2012) 0.81
Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations. J Pharmacokinet Pharmacodyn (2015) 0.81
Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). Xenobiotica (2007) 0.81
Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci (2006) 0.81
Evaluation of an existing nomogram for predicting the response to clomiphene citrate. Fertil Steril (2006) 0.80
Influence of the thr164ile polymorphism in the beta2-adrenoceptor on the effects of beta-adrenoceptor agonists on human lung mast cells. Int Immunopharmacol (2003) 0.80
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J Clin Pharmacol (2007) 0.80
CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet (2008) 0.79
Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. J Proteome Res (2013) 0.79
Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. J Clin Psychopharmacol (2012) 0.79
Cytochrome P450 Pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectrometry [corrected]. Drug Metab Dispos (2011) 0.79
Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos (2010) 0.79
Can saliva replace plasma for the monitoring of methadone? Ther Drug Monit (2005) 0.79
Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharm Res (2003) 0.79